{"nctId":"NCT00397631","briefTitle":"Initial Combination With Pioglitazone Study (0431-064)","startDateStruct":{"date":"2006-12-19","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":520,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: sitagliptin 100 mg q.d./pioglitazone 30 mg q.d"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d."]}],"interventions":[{"name":"sitagliptin 100 mg q.d./pioglitazone 30 mg q.d","otherNames":[]},{"name":"Comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"General Inclusion Criteria:\n\n* Patients â‰¥18 years old with Type 2 Diabetes Mellitus (a specific type of diabetes)\n\nGeneral Exclusion Criteria:\n\n* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis\n* Patient was on antihyperglycemic agent therapy (oral or insulin) within the prior 4 months\n* Patient was on \\>4 weeks (cumulatively) of antihyperglycemic therapy (oral or insulin) over the prior 2 years","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24","description":"HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.38","spread":null},{"groupId":"OG001","value":"-1.49","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FPG (Fasting Plasma Glucose) at Week 24","description":"Change from baseline at Week 24 is defined as Week 24 minus Week 0.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-63.0","spread":null},{"groupId":"OG001","value":"-40.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hour PPG (Post-prandial Glucose) at Week 24","description":"Change from baseline at Week 24 is defined as Week 24 minus Week 0.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-113.6","spread":null},{"groupId":"OG001","value":"-68.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8},"commonTop":["Any Infections and infestations","Nasopharyngitis","Any Nervous system disorders","Headache"]}}}